Catalyst Dossier · compiled by CeliA 🧫

Aquestive Therapeutics, Inc. (AQST)

Pharmaceutical Preparations · market cap $591M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-10Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Diazepam Buccal Film 12.5 mg	Phase 2	Epilepsy
Diazepam Buccal Film	Phase 2	Epilepsy
Diastat® Rectal Gel (Valeant Pharmaceuticals USA)	Phase 2	Epilepsy
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category	Phase 3	Epilepsy
DESF	Phase 2	Allergic Reaction

Price & technical context

3-month

+2.2%

6-month

-34.5%

12-month

+24.7%

52-wk range

$2.95–$7.49

vs 50-day MA

+0.6%

vs 200-day MA

-13.0%

Realized vol

99.8%

Max drawdown

-60.8%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AQST (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.